Tag Archives: Crestovo

June 27, 2017

Crestovo Doses Patients in PRISM 3, a Clinical Trial of CP101, a Microbiome Therapy for the Prevention of Recurrent Clostridium difficile Infection

CP101 is the lead, orally-administered product generated from Crestovo’s Full-Spectrum MicrobiotaTM (FSMTM) platform PRISM 3 includes 240 patients at clinical sites with broad coverage throughout the U.S. The company is based on foundational clinical research from gut microbiota-based treatment pioneers, Dr. Thomas J. Borody, Dr. Alexander Khoruts and Dr. Michael J. Sadowsky June 27, 2017 […]

CDD news